Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASA404 plus docetaxel versus placebo plus docetaxel in second-line advanced or metastatic non-small cell lung cancer
2008-002309-38Phase 3Terminated
- Sponsor
- Novartis
- Start
- Oct 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing ASA404 + docetaxel with Placebo + docetaxel (2 arms). Primary endpoint: overall survival. Started Oct 2008; status: terminated.
02
Drugs
vadimezandocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-002309-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002309-38.